{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:15:10Z","timestamp":1793459710016,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.lanepe.2023.100657","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T23:17:07Z","timestamp":1684711027000},"page":"100657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5751-6292","authenticated-orcid":false,"given":"Linus","family":"J\u00f6nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Handels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Gavin","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Kramberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"de Mendon\u03c2a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Jean","family":"Ousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Scarmeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Waldemar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-1179","authenticated-orcid":false,"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lanepe.2023.100657_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/alz.12450","article-title":"The costs of developing treatments for Alzheimer\u2019s disease: a retrospective exploration","volume":"18","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100657_bib2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.lanepe.2023.100657_bib5","series-title":"Withdrawal assessment report for aduhelm","author":"EMA","year":"2022"},{"key":"10.1016\/j.lanepe.2023.100657_bib6","author":"Scott"},{"key":"10.1016\/j.lanepe.2023.100657_bib7","series-title":"Aducanumab for Alzheimer\u2019s disease: effectiveness and value; final evidence report and meeting summary","author":"Lin","year":"2021"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100657_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.lanepe.2023.100657_bib9","author":"FDA"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100657_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2023.100657_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100657_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanepe.2023.100657_bib14","series-title":"The pharmaceutical industry in figures - ked data 2022","author":"EFPIA","year":"2022"},{"key":"10.1016\/j.lanepe.2023.100657_bib15","series-title":"Lecanemab: appropriate use recommendations","author":"Cummings","year":"2023"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100657_bib16","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment","volume":"8","author":"Hlavka","year":"2019","journal-title":"Rand Health Q"},{"key":"10.1016\/j.lanepe.2023.100657_bib17","series-title":"Rethinking Alzheimer's disease detection and diagnosis","year":"2023"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100657_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.26352","article-title":"Decreasing multiple sclerosis treatment expenditures and improving quality at the health system level","volume":"92","author":"Langer-Gould","year":"2022","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100657_bib19","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100657_bib20","doi-asserted-by":"crossref","first-page":"e029663","DOI":"10.1136\/bmjopen-2019-029663","article-title":"How many patients are eligible for disease-modifying treatment in Alzheimer\u2019s disease? A French national observational study over 5 years","volume":"9","author":"Epelbaum","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2023.100657_bib21","series-title":"A path to improved Alzheimer\u2019s care: simulating long-term health outcomes of lecanemab in early Alzheimer\u2019s disease from the CLARITY AD trial","author":"Tahami Monfared","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100657_bib22","series-title":"Estimated societal value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","author":"Tahami Monfared","year":"2023"},{"issue":"9","key":"10.1016\/j.lanepe.2023.100657_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.lanepe.2023.100657_bib24","series-title":"B\u00f6r l\u00e4kemedelskostnaderna ombalanseras? \u2013 En samh\u00e4llsekonomisk analys","author":"Bergman","year":"2022"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100657_bib25","article-title":"Lecanemab: the price of a Breakthrough","volume":"19","author":"Wimo","year":"2023","journal-title":"Touch Neurol"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100657_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.healthpol.2017.02.002","article-title":"Payers' experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia","volume":"121","author":"Morgan","year":"2017","journal-title":"Health Pol"},{"issue":"9","key":"10.1016\/j.lanepe.2023.100657_bib27","article-title":"Confidential drug prices undermine trust in the system","volume":"139","author":"Tranvag","year":"2019","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100657_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40273-022-01212-z","article-title":"The costs of dementia in Europe: an updated review and meta-analysis","volume":"41","author":"Jonsson","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100657_bib29","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12603-010-0311-7","article-title":"Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study","volume":"14","author":"Gustavsson","year":"2010","journal-title":"J Nutr Health Aging"},{"issue":"Suppl_1","key":"10.1016\/j.lanepe.2023.100657_bib30","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/eurpub\/ckaa033","article-title":"Leaving no one behind: health equity as a catalyst for the sustainable development goals","volume":"30","author":"Buzeti","year":"2020","journal-title":"Eur J Publ Health"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:55:52Z","timestamp":1763009752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776223000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"alternative-id":["S2666776223000765"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100657","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100657"}}